Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report)'s share price traded down 2.9% on Tuesday . The stock traded as low as $22.53 and last traded at $22.74. 10,609 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 253,241 shares. The stock had previously closed at $23.43.
Analyst Ratings Changes
ELVN has been the subject of a number of recent research reports. BTIG Research initiated coverage on Enliven Therapeutics in a report on Friday, December 13th. They issued a "buy" rating and a $42.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Finally, Robert W. Baird raised their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an "outperform" rating in a research report on Friday, November 15th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Enliven Therapeutics has a consensus rating of "Buy" and a consensus price target of $38.25.
Check Out Our Latest Research Report on Enliven Therapeutics
Enliven Therapeutics Price Performance
The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -12.18 and a beta of 1.02. The firm's fifty day moving average is $26.02 and its 200-day moving average is $24.26.
Insider Activity at Enliven Therapeutics
In other Enliven Therapeutics news, CFO Benjamin Hohl sold 2,000 shares of the firm's stock in a transaction on Monday, September 30th. The shares were sold at an average price of $25.33, for a total value of $50,660.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Joseph P. Lyssikatos sold 7,522 shares of the company's stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $27.51, for a total transaction of $206,930.22. Following the transaction, the insider now owns 1,069,887 shares in the company, valued at $29,432,591.37. This represents a 0.70 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 129,195 shares of company stock worth $3,581,772 in the last 90 days. Corporate insiders own 29.20% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in ELVN. Quest Partners LLC raised its position in shares of Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company's stock worth $37,000 after purchasing an additional 742 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Enliven Therapeutics by 12.7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,168 shares of the company's stock worth $668,000 after buying an additional 2,944 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Enliven Therapeutics by 25.6% in the third quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company's stock valued at $441,000 after buying an additional 3,518 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Enliven Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company's stock valued at $232,000 after buying an additional 3,559 shares during the last quarter. Finally, American Century Companies Inc. increased its position in shares of Enliven Therapeutics by 44.7% during the second quarter. American Century Companies Inc. now owns 27,651 shares of the company's stock worth $646,000 after acquiring an additional 8,540 shares in the last quarter. Institutional investors own 95.08% of the company's stock.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Recommended Stories
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
